New Appointments for Carlos Lozada, MD In the midst of the coronavirus pandemic, Carlos J. Lozada, MD, FACP, FACR, professor of clinical medicine, University of Miami Miller School of Medicine, has expanded his professional and volunteer duties. In May he was appointed chief (interim) of the Division of Rheumatology at the Miller School of Medicine,…
Reactive arthritis is classically associated with an infectious etiology, such as Salmonella, Yersinia, Campylobacter, Chlamydia or gonorrhea. Clostridium difficile is a rare, and recently recognized, causative agent for this condition.1 Case Presentation The patient is a 21-year-old man with a past medical history significant for hereditary spherocytosis and Crohn’s disease, complicated by an anorectal fistula,…
A proposed biomarker may improve the diagnosis of rheumatoid arthritis (RA). Writing in Arthritis & Rheumatology, researchers at Pleasanton, Calif.-based Roche Sequencing Solutions and the University of Toronto say their biomarker, constructed by profiling a comprehensive set of antibodies via high-density peptide array, has high specificity and sensitivity for RA, compared with commercially available assays.1…
As founder and president of a large rheumatology group, Howard M. Busch, DO, says the pandemic has had a limited financial effect on many of the network’s clinics. Communication and technology have been key to adapting to the needs of patients and connecting with other providers during this critical time.
With a new Congress and many new legislators in key leadership positions, your support today will help RheumPAC start the year off strong.
A young man sits down at my COVID-19 immunization station at Maine Medical Center and stares resolutely ahead, focusing on the far wall. He looks nervous. I make sure the needle and syringe are outside his field of vision. That should help. I pick up a Band-Aid from my box of supplies. It’s a Band-Aid…
Hydroxychloroquine may not increase the risk of cardiotoxicity in RA patients, according to findings presented during ACR Convergence 2020.
Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.
In an ACR Convergence session, two rheumatologists discussed how COVID-19 changed the use of telemedicine, how payers reacted and which changes are likely permanent and which are likely to be temporary.
ACR Convergence panelists discussed how to monitor SSc-ILD patients for ILD severity & the brightening prospects for therapy.